These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22543826)

  • 21. Patient empowerment in the management of chronic myeloid leukemia.
    Coleman M
    Clin J Oncol Nurs; 2014 Apr; 18(2):E12-8. PubMed ID: 24675265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Origin of resistance to Imatinib mesylate: lessons learned from this experience].
    Roche-Lestienne C; Mahon FX; Preudhomme C
    Med Sci (Paris); 2004 Dec; 20(12):1125-30. PubMed ID: 15581468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health-related quality of life in chronic myeloid leukemia.
    Trask PC; Cella D; Powell C; Reisman A; Whiteley J; Kelly V
    Leuk Res; 2013 Jan; 37(1):9-13. PubMed ID: 23116602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
    Roche-Lestienne C; Darré S; Laï JL; Facon T; Guilhot J; Preudhomme C
    Haematologica; 2005 Jan; 90(1):131-3. PubMed ID: 15642682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP).
    Chen Z; Wang C; Xu X; Feng W
    Value Health; 2009; 12 Suppl 3():S85-8. PubMed ID: 20586990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imatinib results in better quality of life for CML patients than interferon/Ara-C.
    J Support Oncol; 2003; 1(1):77. PubMed ID: 15352651
    [No Abstract]   [Full Text] [Related]  

  • 30. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cytogenetic response as a marker of efficacy of chronic myeloid leukemia therapy with a BCR-ABL thyrosine kinase inhibitor glivek].
    Turkina AG; Kruglov SS; Druzhkova GA; Domracheva EV; Zakharova AV; Vinogradova OIu; Sysoeva EP; Diachenko LV; Chelysheva EIu; Zakharova ES; Abakumov EM; Kolosheĭnova TI; Kolosova LIu; Ivanova TV; Zhuravlev VS; Nemchenko IS; Zingerman BV; Kurova ES; Triputen' NZ; Loriia SS; Kovaleva LG; Khoroshko ND
    Ter Arkh; 2005; 77(7):42-7. PubMed ID: 16116908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response.
    Usman M; Syed NN; Kakepoto GN; Adil SN; Khurshid M
    J Assoc Physicians India; 2007 Feb; 55():103-7. PubMed ID: 17571738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
    Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA;
    N Engl J Med; 2006 Dec; 355(23):2408-17. PubMed ID: 17151364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
    Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.
    Efficace F; Baccarani M; Breccia M; Alimena G; Rosti G; Cottone F; Deliliers GL; Baratè C; Rossi AR; Fioritoni G; Luciano L; Turri D; Martino B; Di Raimondo F; Dabusti M; Bergamaschi M; Leoni P; Simula MP; Levato L; Ulisciani S; Veneri D; Sica S; Rambaldi A; Vignetti M; Mandelli F;
    Blood; 2011 Oct; 118(17):4554-60. PubMed ID: 21750313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognitive Behavioral Therapy for Treatment-Related Fatigue in Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitors: A Mixed-Method Study.
    Poort H; Onghena P; Abrahams HJG; Jim HSL; Jacobsen PB; Blijlevens NMA; Knoop H
    J Clin Psychol Med Settings; 2019 Dec; 26(4):440-448. PubMed ID: 30747340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia.
    Efficace F; Rosti G; Aaronson N; Cottone F; Angelucci E; Molica S; Vignetti M; Mandelli F; Baccarani M
    Haematologica; 2014 Apr; 99(4):788-93. PubMed ID: 24241488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health-related quality of life using EQ-5D among chronic myeloid leukaemia patients in health centres in Klang Valley, Malaysia.
    Wan Puteh SE; Aizuddin AN; Tumian NR; Sathar J; Mohamad Selamat E
    PLoS One; 2021; 16(8):e0256804. PubMed ID: 34449814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia.
    Efficace F; Rosti G; Breccia M; Cottone F; Giesinger JM; Stagno F; Iurlo A; Russo Rossi A; Luciano L; Martino B; Galimberti S; Turri D; Bergamaschi M; Tiribelli M; Fava C; Angelucci E; Mandelli F; Baccarani M
    Ann Hematol; 2016 Jan; 95(2):211-9. PubMed ID: 26546359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.